Study M835

Study name	Tian T 2021
Title	Multi-omics data reveals the disturbance of glycerophospholipid metabolism caused by disordered gut microbiota in depressed mice
Overall design	The aim of this study was to find out how the gut microbiota was involved in the onset of depression, and to identify the potential ways to link the gut and brain in mice with depressive-like behaviors. The chronic restraint stress (CRS) model of depression was used in this study. C57BL/6 mice were divided into the following 2 groups (n = 10 per group): (1) control group, and (2) CRS group. The CRS stress procedure lasted for 4 weeks. The lipid metabolites in three kinds of biological samples (fecal, serum and hippocampus) and 15 neurotransmitters in hippocampus samples are detected by LC-MS.
Study Type	Type1;
Data available	Unavailable
Organism	Mouse; C57BL/6 mouse;
Categories of depression	Animal model; Chronic restraint stress model; Chronic restraint stress model;
Criteria for depression	Sucrose preference test, forced swimming test
Sample size	20
Tissue	Peripheral; Faece; Faece; Peripheral; Blood; Serum; Central; Brain; Hippocampus;
Platform	MS-based; LC-MS: ACQUITY I Class UPLC system with Waters G2-S QTOF system (Waters, Milford, MA, USA);
PMID	35777903
DOI	10.1016/j.jare.2021.10.002
Citation	Tian T, Mao Q, Xie J, et al. Multi-omics data reveals the disturbance of glycerophospholipid metabolism caused by disordered gut microbiota in depressed mice. Journal of Advanced Research. 2021.
Metabolite	L-Tryptophan; Pimelic acid; L-Tyrosine; 5-Hydroxyindoleacetic acid; LysoPC(16:0); Indoleacetic acid; Serotonin; Acetic acid; Indolelactic acid; 4-Hydroxybutyric acid; PC(32:1); Palmitic amide; Butyric acid; LysoPE(0:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)); DG(18:1(9Z)/18:2(9Z,12Z)/0:0); Pentadecanol; Propionic acid; 3-Hydroxyisovalerylcarnitine; PI(38:3); PC(18:0/18:2); Methyl linoleate; LysoPC(18:3(6Z,9Z,12Z)); LysoPE(0:0/20:2(11Z,14Z)); PS(15:0/22:0); LysoPC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0); DG(20:2n6/0:0/20:5n3); 5-Phenylvaleric acid; Indole; Undecanoic acid; SM(d18:1/15:0); Sorbitan stearate; Lysylhistidine; PC(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)); PS(18:1/18:2); PI(18:0/18:0); LysoPC(24:1(15Z)/0:0); Glutarate semialdehyde; gamma-Glutamyltyrosine; MG(0:0/16:1(9Z)/0:0); PGP(16:0/18:0); 3-keto Fusidic acid; LysoPC(P-18:0/0:0); LysoPC(22:5(7Z,10Z,13Z,16Z,19Z)/0:0); DG(14:1n5/0:0/22:6n3); CPA(18:1(9Z)/0:0); LysoPE(20:1(11Z)/0:0); 1-(11Z-eicosenoyl)-glycero-3-phosphate; 1-(11Z-docosenoyl)-glycero-3-phosphate; DG(14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0); PI(16:0/20:2(11Z,14Z)); Dethiobiotin; LysoPC(18:1(9Z)/0:0); PS(18:3/20:4); Valproic acid; 3-Methylindole; PE(18:0/18:0); PC(16:0/14:0); PC(16:0/16:1); SM(t42:1); AEA(18:2); PE(20:0e/22:6); PE(16:0/16:1); CL(18:1/16:0/16:0/16:1); PC(56:4); MGDG(16:0e/20:1); CL(20:5/20:4/20:4/16:1); MGDG(16:0/18:0); PS(40:8e); Hex1Cer(d16:0/20:4); dMePE(18:1/22:6); PC(39:3); PC(42:9); Isononanoic acid; Dehydro-4-methoxycyclobrassinin; PC(12:0/20:5(5Z,8Z,11Z,14Z,17Z)); LysoPE(0:0/24:0); PA(O-20:0/0:0); 10-Hydroxymyristic acid methyl ester; 11beta,20-Dihydroxy-3-oxopregn-4-en-21-oic acid; LysoPA(0:0/18:2(9Z,12Z)); PC(14:0/16:1(9Z)); (2E,4E)-2,7-Dimethyl-2,4-octadienedioic acid; Galactosylglycerol; Oryzanol A; Ganoderic acid epsilon; Kaempferol 3-sophoroside 7-glucoside; N-Acetyl-6-O-L-fucosyl-D-glucosamine; Ciclesonide; PIP(18:3(9Z,12Z,15Z)/18:0); PA(10:0/19:0); 8Z,11Z-eicosadienoic acid; Hexyl heptanoate; LysoPS(18:0/0:0); Corchorusoside C; (2'E,4'Z,8E)-Colneleic acid; DG(16:1(9Z)/15:0/0:0); PA(22:4(7Z,10Z,13Z,16Z)/15:0); DG(14:0/20:4(5Z,8Z,11Z,14Z)/0:0); Asterosterol; 3-Methyl-5-pentyl-2-furanpentadecanoic acid; Floionolic acid; PC(14:1(9Z)/14:1(9Z)); 2-Hydroxy-2-ethylsuccinic acid; Armexifolin; S-Furanopetasitin; Tridecanal; LysoPI(20:0/0:0); Palmitoyl Serinol; 2alpha-Hydroxyalantolactone; DG(14:1(9Z)/22:4(7Z,10Z,13Z,16Z)/0:0); 3-Hexenoic acid; MG(0:0/18:1(11Z)/0:0); Citroside A; 2-(8-hydroxy-3,7-dimethylocta-2,6-dien-1-yl)benzene-1,3,5-triol; TG(18:4/18:4/22:5); Endrin; Triacylglycerol; Isobornyl isobutyrate; 5C-aglycone; Sarmentosin; Norecasantalal; Perillic acid; Calamin; PS(14:1(9Z)/22:0); Diisopentyl thiomalate; PA(8:0/8:0); TG(15:0/16:0/18:0); 5,9,11-trihydroxyprosta-6E,14Z-dien-1-oate; 2,6,10,15-tetramethylheptadecane; cis-4-Decenedioic acid; Lycoperoside D; Octadecyl fumarate; Glaucarubol 15-O-beta-D-glucopyranoside; TG(16:1(9Z)/14:1(9Z)/16:1(9Z)); PIP3(18:2(9Z,12Z)/20:1(11Z)); trans-3-Decenoyl-CoA; 3,4,5-trihydroxy-6-{[1-(4-methoxyphenyl)pentan-3-yl]oxy}oxane-2-carboxylic acid; TG(i-12:0/8:0/i-16:0); PI(P-16:0/16:1(9Z)); Licoricesaponin B2; TG(16:0e/18:2/18:3); Pipericine; DG(10:0/a-25:0/0:0); (3beta,22E,24R)-Ergosta-4,6,8(14),22-tetraen-3-ol; Lucidenic acid I; 6-Deoxodolichosterone; LysoPI(18:1(9Z)/0:0); TG(24:0/24:0/24:0); Methyl 3b-hydroxy-13(18)-oleanen-28-oate; 3-Oxoalanine; Oseltamivir; MG(O-18:0/0:0/0:0); Cer(d17:1/16:0); Butyramide; DG(20:0/22:0/0:0); (R)-2-Hydroxyhexadecanoic acid; Linalyl anthranilate; Lycoperdic acid; PGP(16:1(9Z)/16:1(9Z)); PG(16:0/18:0); 2-Butyl-1-octanol; PS(DiMe(9,5)/MonoMe(13,5)); CE(15M5); 7-Sulfocholic acid; DG(22:2(13Z,16Z)/24:1(15Z)/0:0); Asparaginyl-Proline; 3-Hexaprenyl-4-hydroxy-5-methoxybenzoic acid; Glycocholic acid 3-sulfate; (R)-3-Hydroxy-Octadecanoic acid; LysoPA(21:0/0:0); Ganoderol B; 5-HPETE; PG(15:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)); PA(16:0/18:2(9Z,12Z)); Necatorine; Betalamic acid; MG(20:4(8Z,11Z,14Z,17Z)/0:0/0:0); TG(14:1(9Z)/16:1(9Z)/16:1(9Z)); ent-Kaur-16-en-19-al; PC(14:0/P-18:0); TG(8:0/18:0/10:0); gamma-Tocopheryl quinone; PE-Cer(d16:1(4E)/24:1(15Z)); (2E,4E)-2,4-Hexadienoic acid; 11,12,15-trihydroxyeicosatrienoic acid; Hexacosanoyl carnitine; 3,4-Dimethyl-5-pentyl-2-furanundecanoic acid; PE(15:0/18:3(6Z,9Z,12Z)); PGP(a-13:0/i-22:0); PE-NMe2(16:0/18:1(9Z)); Heptacosanoic acid; Dihydrozeatin-O-glucoside; Rosmic acid; PC(24:1(15Z)/24:1(15Z)); Carnosic acid; PA(10:0/8:0); CL(i-14:0/i-12:0/i-12:0/i-17:0); DG(14:0/16:0/0:0); (E)-10-Hydroxy-2-decene-4,6-diynoic acid; L-Agaritine; (E)-10-Oxo-8-decenoic acid; Galactosylceramide (d18:1/18:0); beta-Citraurinene; LysoPC(20:3(5Z,8Z,11Z)/0:0); LysoPS(18:1(9Z)/0:0); Sciadonic acid; Pentadecanal; Fusidic Acid; PC(37:3e); N-Undecanoylglycine; 3-Hydroxy-5Z-octenyl acetate; Ethyl 3-mercaptobutyrate; LysoPE(24:6(6Z,9Z,12Z,15Z,18Z,21Z)/0:0); PA(10:0/17:0); PA(22:1(13Z)/24:1(15Z)); LysoPG(16:0/0:0); CL(8:0/8:0/10:0/18:2(9Z,11Z)); PG(15:1(9Z)/16:0); TG(22:5(7Z,10Z,13Z,16Z,19Z)/18:0/o-18:0); 13,14-Dihydro PGF-1a; Eicosapentaenoic acid ethyl ester; Thujyl alcohol; (24E)-3alpha-Acetoxy-15alpha-hydroxy-23-oxo-7,9(11),24-lanostatrien-26-oic acid; LysoPC(18:1(11Z)/0:0); Lucyobroside; Cyclohexaneundecanoic acid; Methyl 15-cyanopentadecanoate; DG(20:3n9/0:0/20:2n6); PC(20:5(5Z,8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z)); TG(15:0/22:5(4Z,7Z,10Z,13Z,16Z)/15:0); CE(18:2(9Z,12Z)); PE-NMe2(14:0/16:1(9Z)); CL(18:0/18:0/18:0/18:0); Agavoside B; ent-16-Kauren-19-ol acetate; DG(20:2n6/0:0/20:4n6); Glutamylmethionine; Vitamin D2 3-glucuronide; Corchoionol C 9-glucoside; PC(O-18:1(9Z)/O-1:0); TG(16:0e/16:0/18:2); Glycerol 1-propanoate diacetate; 9,10,13-TriHOME; CDP-DG(18:2(9Z,11Z)/a-25:0); PE-NMe(11D5/13D5); Assafoetidin; DG(15:0/0:0/16:1n7); DG(14:0/20:5(5Z,8Z,11Z,14Z,17Z)/0:0); C12H23NO2S; 12-Ketoporrigenin; CPA(18:1(11Z)/0:0); 3-Methyl-alpha-ionyl acetate; CL(8:0/i-17:0/18:2(9Z,11Z)/18:2(9Z,11Z)); Cer(d18:0/22:1(13Z)); TG(16:0e/18:2/18:2); FAHFA(16:1(9Z)/12-O-18:0); 2-Methyl-5-isopropylhexa-2Z,5-dienal; Finasteride; DG(19:0/0:0/i-24:0); Hovenidulcioside B2; PGF2a ethanolamide; Ganglioside GM3 (d18:0/25:0); N-Nitrosotomatidine; 9-peroxy-5Z,7E,11Z,14Z-eicosatetraenoate; PI(18:1(11Z)/18:1(11Z)); 3-Hydroxy-4,6-heptadiyne-1-yl 1-glucoside; DG(15:0/0:0/22:2n6); Prostaglandin D3; 2-O-a-L-Fucopyranosyl-galactose; Triton X 100; TG(18:0e/18:1/18:2); BisMePA(15:0/16:0); TG(16:0e/18:0/18:1); PC(44:6e); PMe(16:0/16:0); PC(42:8e); TG(14:0e/16:0/18:2); PI(18:0/16:0); PI(16:0/22:6); PMe(16:0/18:1); AEA(20:1); TG(20:5/18:2/18:2); LdMePE(16:0); PC(42:4); PC(16:1e/20:4); MePC(33:3e); CerG3GNAc2(d42:1); PC(46:7); PC(40:7e); PC(44:4); PE(20:1p/18:2); MePC(34:8e); PC(40:4e); PE(20:1p/20:4); Cer(t40:1); SM(t33:1); PC(24:0/18:2); PS(38:4e); PE(36:2e); PE(18:0e/18:2); PC(38:0); CL(20:4/18:1/18:1/18:1); TG(18:0/16:0/16:0); PC(19:1/16:0); PS(18:0/22:4);